Employees: 1,868
Size Hunan Fangsheng Pharmaceutical (603998.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $719M, the 2842nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.58 on 18 Nov 2026.
Performance Over six months the shares fell 1.1%, against -14.5% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 11.6% over the last twelve months (peer median -1.9%); the operating margin is 20.3% (peer median 9.6%).
Valuation It trades at 13.7× forward earnings against a peer median of 16.4× (4th cheapest of 9).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 11.2 points above its cost of capital (6.1% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.88B | CN¥1.73B | CN¥1.76B | CN¥1.61B | CN¥1.78B |
| Revenue growth | — | -2% | +9% | -9% | — |
| Gross profit | CN¥1.43B | CN¥1.19B | CN¥1.21B | CN¥1.04B | CN¥1.13B |
| EBITDA | n/a | CN¥391M | CN¥324M | CN¥243M | CN¥229M |
| Net income | CN¥327M | CN¥306M | CN¥255M | CN¥187M | CN¥286M |
| Free cash flow | CN¥544M | CN¥342M | CN¥100M | -CN¥130M | CN¥133M |
| Capital expenditure | CN¥104M | CN¥103M | CN¥94.8M | CN¥219M | CN¥171M |
| Total debt | CN¥230M | CN¥471M | CN¥764M | CN¥829M | CN¥659M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603998.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.8% | -7.1% | 7th highest of 21 |
| 6-month return | -1.1% | -14.5% | 6th highest of 21 |
| Distance from 52-week high | -21.6% | -35.0% | 6th highest of 21 |
| Revenue growth (TTM) | +11.6% | -1.9% | 3rd highest of 19 |
| Operating margin | 20.3% | 9.6% | 3rd highest of 19 |
| Forward P/E | 13.7× | 16.4× | 4th cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | -4.8% | 0.3% | 3rd least demanding of 12 |
| Growth delivered (Del g) | +6.4% | 0.0% | 3rd highest of 12 |
| Hurdle (Req g minus delivered) | -11.2 pp | -1.4 pp | 3rd least demanding of 12 |
| ROIC minus cost of capital | +11.2 pp | +0.5 pp | 2nd highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 13.7× | -4.8% | +6.4% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | n/a | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 16.1× | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 47.6× | n/a | n/a |
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | n/a | 42.7% | -0.9% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $727M | -9% | +8% | 26% | 11.2× | 5.9% | +11.3% |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 7.1× | -11.8% | +1.9% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | n/a | 4.0% | +5.3% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $738M | -20% | -5% | 13% | 16.7× | -2.0% | +26.1% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | n/a | -2.1% | 0.0% |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 18.0× | -1.6% | -1.8% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | n/a | n/a | n/a |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 9.1× | n/a | n/a |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | n/a | 9.4% | -1.4% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | n/a | 13.5% | -0.2% |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | n/a | -8.3% | -2.8% |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | n/a | 0.3% | +0.5% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | n/a | n/a | n/a |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 24.9× | n/a | n/a |